<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0609</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2026-08-07</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0001638097</issuerCik>
        <issuerName>Entera Bio Ltd.</issuerName>
        <issuerTradingSymbol>ENTX</issuerTradingSymbol>
        <issuerForeignTradingSymbol></issuerForeignTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001904759</rptOwnerCik>
            <rptOwnerName>Malca Yonatan</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerNonUSAddressFlag>true</rptOwnerNonUSAddressFlag>
            <rptOwnerStreet1>KIRYAT HADASSAH</rptOwnerStreet1>
            <rptOwnerStreet2>MINRAV BUILDING, FIFTH FLOOR</rptOwnerStreet2>
            <rptOwnerCity>JERUSALEM</rptOwnerCity>
            <rptOwnerNonUSStateTerritory></rptOwnerNonUSStateTerritory>
            <rptOwnerCountry>L3</rptOwnerCountry>
            <rptOwnerZipCode>9112002</rptOwnerZipCode>
            <rptOwnerStateDescription>ISRAEL</rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle></officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>0</aff10b5One>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Ordinary Shares, par value NIS 0.0000769 per share</value>
            </securityTitle>
            <transactionDate>
                <value>2026-08-07</value>
            </transactionDate>
            <deemedExecutionDate></deemedExecutionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
                <footnoteId id="F1"/>
            </transactionCoding>
            <transactionTimeliness></transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>22815</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>100231</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <footnotes>
        <footnote id="F1">The Board of Directors (the &quot;Board&quot;) of Entera Bio Ltd. (the &quot;Company&quot;) awarded these shares to the Reporting Person in lieu of the cash fees the Reporting Person was entitled to for services rendered as a director of the Company for the first quarter and second quarter of 2026. This grant of shares was approved by the Board on August 5, 2026, subject to the filing by the Company of a Registration Statement on Form S-8 registering the shares, which occurred on August 7, 2026.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Dana Yaacov-Garbeli, Attorney-in-Fact</signatureName>
        <signatureDate>2026-08-07</signatureDate>
    </ownerSignature>
</ownershipDocument>
